Nona Biosciences, a wholly owned subsidiary of HBM Holdings Ltd., has entered into a license agreement with Visterra, Inc. to advance its next-generation biotherapeutic pipeline for immune-mediated and autoimmune diseases. The collaboration will leverage Nona Biosciences' proprietary heavy-chain-only antibody (HCAb) Harbour Mice® technology platform, which enables the generation of fully human HCAbs. This platform offers advantages such as reduced immunogenicity and enhanced versatility for biotherapeutic development. Nona Biosciences is a global biotechnology company focused on innovation and providing integrated solutions from target validation to preclinical research, utilizing its Harbour Mice® platforms and experienced discovery team.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.